Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
Yang SW, Smotryski J, McElroy WT, Tan Z, Ho G, Tulshian D, Greenlee WJ, Guzzi M, Zhang X, Mullins D, Xiao L, Hruza A, Chan TM, Rindgen D, Bleickardt C, Hodgson R.
Yang SW, et al. Among authors: chan tm.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):235-9. doi: 10.1016/j.bmcl.2011.11.023. Epub 2011 Nov 16.
Bioorg Med Chem Lett. 2012.
PMID: 22142545